Not applicableStudy completedNCT01541618What this trial is testingMSDx Complex 1 as a Marker for Therapy Response in Multiple SclerosisWho this might be right forRelapsing Remitting Multiple Sclerosis MSDx, Inc. 15
Testing effectiveness (Phase 2)Study completedNCT02782858What this trial is testingClinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MSWho this might be right forMultiple Sclerosis, Relapsing-Remitting GeNeuro SA 270
Large-scale testing (Phase 3)Study completedNCT02555215What this trial is testingExtension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)Who this might be right forMultiple Sclerosis, Relapsing-Remitting Biogen 20
Large-scale testing (Phase 3)Ended earlyNCT01578785What this trial is testingAn Efficacy, Safety and Tolerability Study of Glatiramer Acetate (GA) 20 mg/0.5 ml New Formulation Administered Daily by Subcutaneous (SC) Injection in Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)Who this might be right forRelapsing-Remitting Multiple Sclerosis Teva Branded Pharmaceutical Products R&D, Inc. 178
Large-scale testing (Phase 3)Study completedNCT04966338What this trial is testingEfficacy and Safety of Xacrel® (Ocrelizumab) in Participants With Relapsing Remitting Multiple SclerosisWho this might be right forMultiple SclerosisRelapsing-Remitting Cinnagen 170
Post-approval studies (Phase 4)Study completedNCT01085318What this trial is testingRebif Advanced Magnetic Resonance Imaging (MRI) and Immunology Pilot TrialWho this might be right forMultiple Sclerosis EMD Serono 38
Testing effectiveness (Phase 2)Study completedNCT00893217What this trial is testingBEYOND Pilot StudyWho this might be right forMultiple SclerosisRelapsing-Remitting Bayer 71
Testing effectiveness (Phase 2)Study completedNCT00235989What this trial is testingExtension of Prior Study Evaluating Safety and Tolerability of Two Doses of Betaseron® to Treat Relapsing-remitting Multiple SclerosisWho this might be right forMultiple Sclerosis, Relapsing-Remitting Bayer 63
Post-approval studies (Phase 4)Study completedNCT02142205What this trial is testingSafety and Efficacy of Natalizumab (BG00002, Tysabri®) in Russian Participants With Relapsing Remitting Multiple Sclerosis (RRMS)Who this might be right forRelapsing-Remitting Multiple Sclerosis Biogen 100
Testing effectiveness (Phase 2)Active Not RecruitingNCT03846219What this trial is testingMRI Trial to exPlore the efficAcy and Safety of IMU-838 in Relapsing Remitting Multiple Sclerosis (EMPhASIS)Who this might be right forRelapsing-Remitting Multiple Sclerosis (RRMS) Immunic AG 210
Post-approval studies (Phase 4)UnknownNCT02325440What this trial is testingStudy to Assess Immune Function and MRI Disease Activity in RRMS Patients When Switching From Natalizumab to GilenyaWho this might be right forRelapsing Remitting Multiple Sclerosis University Hospital Muenster 15
Testing effectiveness (Phase 2)Study completedNCT01428726What this trial is testingA Phase IIa Study of NT-KO-003 for Multiple SclerosisWho this might be right forRelapsing Remitting Multiple Sclerosis Neurotec Pharma 99
Large-scale testing (Phase 3)Active Not RecruitingNCT05123703What this trial is testingEvaluate Safety and Efficacy of Ocrelizumab in Comparison With Fingolimod in Children and Adolescents With Relapsing-remitting Multiple Sclerosis (RRMS)Who this might be right forRelapsing-remitting Multiple Sclerosis Hoffmann-La Roche 188
Testing effectiveness (Phase 2)Study completedNCT01116427What this trial is testingA Cooperative Clinical Study of Abatacept in Multiple SclerosisWho this might be right forMultiple Sclerosis, Relapsing-Remitting National Institute of Allergy and Infectious Diseases (NIAID) 65
Large-scale testing (Phase 3)Study completedNCT01707992What this trial is testingThe Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)Who this might be right forMultiple Sclerosis Teva Branded Pharmaceutical Products R&D, Inc. 2,199
Testing effectiveness (Phase 2)Study completedNCT00097331What this trial is testingThree Months Treatment With SB683699 In Patients With Relapsing Multiple SclerosisWho this might be right forMultiple Sclerosis, Relapsing-Remitting GlaxoSmithKline 261
Large-scale testing (Phase 3)Ended earlyNCT01499667What this trial is testingDisease Control and Safety in Patients With Relapsing Remitting Multiple Sclerosis (RRMS) Switching From Natalizumab to FingolimodWho this might be right forRelapsing Remitting Multiple Sclerosis (RRMS) Novartis Pharmaceuticals 142
Not applicableStudy completedNCT00884481What this trial is testingEffects of Tysabri (BG00002) Over 12 Months on MS Related Fatigue in Participants With RRMSWho this might be right forRelapsing-Remitting Multiple SclerosisFatigue Biogen 195
Large-scale testing (Phase 3)Ended earlyNCT03368664What this trial is testingEvaluate Efficacy, Safety, and Tolerability of Alemtuzumab in Pediatric Patients With RRMS With Disease Activity on Prior DMTWho this might be right forMultiple Sclerosis Genzyme, a Sanofi Company 16
Testing effectiveness (Phase 2)Study completedNCT00451204What this trial is testingA Combination Trial of Copaxone Plus Estriol in Relapsing Remitting Multiple Sclerosis (RRMS)Who this might be right forRelapsing Remitting Multiple Sclerosis University of California, Los Angeles 158